Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2016
At a glance
- Drugs Cemiplimab (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 04 Nov 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 16 May 2016 Status changed from not yet recruiting to recruiting.
- 13 Aug 2015 New trial record